Day One Biopharmaceuticals Inc. (DAWN) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Day One Biopharmaceutical... (DAWN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

11.16

-0.40 (-3.46%)

At close: Jan 14, 2025, 3:59 PM

11.30

1.21%

After-hours Jan 14, 2025, 06:35 PM EST

undefined% (undefined)

Bid	11.12
Market Cap	1.13B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.97
PE Ratio (ttm)	-11.51
Forward PE	n/a
Analyst	Buy

Ask	12.81
Volume	1,926,020
Avg. Volume (20D)	1,077,285
Open	11.58
Previous Close	11.56
Day's Range	11.13 - 11.60
52-Week Range	11.13 - 18.07
Beta	undefined

About DAWN

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral s...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 27, 2021

Employees 174

Stock Exchange NASDAQ

Ticker Symbol DAWN

Website https://dayonebio.com

Analyst Forecast

According to 7 analyst ratings, the average rating for DAWN stock is "Buy." The 12-month stock price forecast is $38, which is an increase of 240.35% from the latest price.

Buy 85.71%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Day One Biopharmaceuticals Inc. is scheduled to release its earnings on Feb 24, 2025, during market hours.
Analysts project revenue of $27.15M, reflecting a n/a YoY growth and earnings per share of -0.48, making a -25.00% decrease YoY.

Why Price Moved

2 months ago · Source

+0.84%

Day One Biopharmaceuticals shares are trading high... Unlock content with Pro Subscription

News

1 week ago · seekingalpha.com

Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)

Day One Biopharmaceuticals focuses on pediatric cancer treatments, with a promising pipeline including tovorafenib and other targeted therapies. The stock has experienced a bearish trend but has signi...

2 weeks ago · zacks.com

3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025

Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025.

3 weeks ago · seekingalpha.com

Day One Biopharmaceuticals: Sales Figures In The Crosshairs

Day One Biopharmaceuticals' key asset, tovorafenib, shows promise in treating pediatric low-grade glioma, with ongoing phase 3 trials aiming to expand its use. DAWN's financial health is strong, with ...

2 months ago · zacks.com

Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?

The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 136.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agre...

2 months ago · seekingalpha.com

Day One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call Transcript

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendin...

2 months ago · zacks.com

Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates

Day One Biopharmaceuticals, Inc. (DAWN) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share. This compares to loss of $0.54 per share...

2 months ago · zacks.com

Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 140.71%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 140.7% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is ques...